News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
723,515 Results
Type
Article (41637)
Company Profile (268)
Press Release (681600)
Multimedia
Podcasts (92)
Webinars (17)
Section
Business (205111)
Career Advice (2082)
Deals (35635)
Drug Delivery (113)
Drug Development (81787)
Employer Resources (173)
FDA (16488)
Job Trends (14987)
News (347417)
Policy (32819)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2590)
Accelerated approval (31)
Adcomms (27)
Allergies (138)
Alliances (49793)
ALS (168)
Alzheimer's disease (1669)
Antibody-drug conjugate (ADC) (317)
Approvals (16741)
Artificial intelligence (511)
Autoimmune disease (147)
Automation (37)
Bankruptcy (364)
Best Places to Work (11663)
BIOSECURE Act (20)
Biosimilars (187)
Biotechnology (174)
Bladder cancer (159)
Brain cancer (57)
Breast cancer (642)
Cancer (4811)
Cardiovascular disease (400)
Career advice (1759)
Career pathing (35)
CAR-T (276)
CDC (46)
Celiac Disease (2)
Cell therapy (732)
Cervical cancer (38)
Clinical research (69819)
Collaboration (1686)
Company closure (4)
Compensation (1138)
Complete response letters (53)
COVID-19 (2721)
CRISPR (89)
C-suite (811)
Cystic fibrosis (143)
Data (6159)
Decentralized trials (2)
Denatured (25)
Depression (131)
Diabetes (500)
Diagnostics (6683)
Digital health (45)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (243)
Drug pricing (186)
Drug shortages (29)
Duchenne muscular dystrophy (226)
Earnings (90075)
Editorial (55)
Employer branding (21)
Employer resources (151)
Events (117382)
Executive appointments (961)
FDA (19565)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1447)
Gene editing (194)
Generative AI (43)
Gene therapy (583)
GLP-1 (972)
Government (4681)
Grass and pollen (6)
Guidances (383)
Healthcare (18924)
HIV (55)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (252)
Immuno-oncology (56)
Indications (103)
Infectious disease (2979)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (242)
Interviews (334)
IPO (16654)
IRA (50)
Job creations (3660)
Job search strategy (1463)
JPM (59)
Kidney cancer (15)
Labor market (83)
Layoffs (546)
Leadership (30)
Legal (7975)
Liver cancer (93)
Longevity (14)
Lung cancer (648)
Lymphoma (375)
Machine learning (43)
Management (59)
Manufacturing (779)
MASH (161)
Medical device (13785)
Medtech (13837)
Mergers & acquisitions (20037)
Metabolic disorders (1266)
Multiple sclerosis (157)
NASH (17)
Neurodegenerative disease (314)
Neuropsychiatric disorders (89)
Neuroscience (2887)
Neurotech (1)
NextGen: Class of 2026 (6548)
Non-profit (4524)
Now hiring (65)
Obesity (593)
Opinion (270)
Ovarian cancer (165)
Pain (196)
Pancreatic cancer (222)
Parkinson's disease (281)
Partnered (33)
Patents (490)
Patient recruitment (470)
Peanut (56)
People (58920)
Pharmaceutical (63)
Pharmacy benefit managers (29)
Phase 1 (21721)
Phase 2 (30702)
Phase 3 (22954)
Pipeline (5090)
Policy (282)
Postmarket research (2590)
Preclinical (9206)
Press Release (64)
Prostate cancer (237)
Psychedelics (49)
Radiopharmaceuticals (277)
Rare diseases (822)
Real estate (5968)
Recruiting (69)
Regulatory (24493)
Reports (51)
Research institute (2397)
Resumes & cover letters (358)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (148)
Series A (237)
Series B (184)
Service/supplier (11)
Sickle cell disease (96)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3623)
State (2)
Stomach cancer (18)
Supply chain (104)
Tariffs (84)
The Weekly (65)
Vaccines (995)
Venture capital (88)
Weight loss (385)
Women's health (87)
Worklife (20)
Date
Last 7 days (595)
Last 30 days (2099)
Last 365 days (29843)
2026 (2828)
2025 (30291)
2024 (35308)
2023 (40146)
2022 (51283)
2021 (55826)
2020 (54204)
2019 (46710)
2018 (35159)
2017 (32212)
2016 (31626)
2015 (37651)
2014 (31431)
2013 (26463)
2012 (28689)
2011 (29384)
2010 (27459)
Location
Africa (747)
Alabama (83)
Alaska (7)
Arizona (306)
Arkansas (13)
Asia (39389)
Australia (6437)
California (11162)
Canada (3256)
China (1099)
Colorado (472)
Connecticut (470)
Delaware (332)
Europe (85021)
Florida (1661)
Georgia (353)
Hawaii (3)
Idaho (62)
Illinois (853)
India (63)
Indiana (513)
Iowa (22)
Japan (419)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1370)
Massachusetts (7996)
Michigan (320)
Minnesota (621)
Mississippi (5)
Missouri (125)
Montana (33)
Nebraska (28)
Nevada (122)
New Hampshire (79)
New Jersey (2966)
New Mexico (28)
New York (2942)
North Carolina (1435)
North Dakota (8)
Northern California (5439)
Ohio (330)
Oklahoma (21)
Oregon (41)
Pennsylvania (2254)
Puerto Rico (22)
Rhode Island (47)
South America (1115)
South Carolina (65)
South Dakota (1)
Southern California (4341)
Tennessee (172)
Texas (1720)
United States (39578)
Utah (333)
Vermont (1)
Virginia (256)
Washington D.C. (81)
Washington State (917)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
723,515 Results for "simulations plus inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
January 9, 2026
·
11 min read
Press Releases
Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results
December 2, 2025
·
13 min read
Press Releases
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
December 17, 2025
·
1 min read
Press Releases
Simulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 Guidance
October 23, 2025
·
7 min read
Press Releases
Simulations Plus Releases ADMET Predictor® 13
June 5, 2025
·
4 min read
Press Releases
Simulations Plus Releases DILIsym® 11
May 15, 2025
·
4 min read
Press Releases
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
July 14, 2025
·
16 min read
Press Releases
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
June 12, 2025
·
1 min read
Business
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024.
June 18, 2024
·
2 min read
Business
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024.
April 3, 2024
·
15 min read
1 of 72,352
Next
